# Lower-Dose CagriSema Cuts Body Weight by About a Fifth

_Evidence Level: Moderate · Wharton S et al., The lancet. Diabetes & endocrinology, DOI 10.1016/S2213-8587(26)00275-5_

*Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.*

- **Evidence Level**: Moderate
- **Why this grade**: A double-blind trial with random assignment in 309 adults over 68 weeks; it is too small and too short to judge rare side effects or long-term effects.
- **Facts**: Design: Randomized controlled trial · Duration: 16 months · Funding: Novo Nordisk
- **Publication Types**: Journal Article
- **Journal**: The lancet. Diabetes & endocrinology
- **Sample Size**: 309 adults in Europe and North America
- **Authors**: Wharton S, Broholm C, Horn D, Pinta AR, Rubino D, Broholm ZR, Bain SC
- **Graded and published**: 2026-11-14
- **Last edited**: 2026-11-20
- **Topics**: GLP-1, Metabolic Health
- **DOI**: https://doi.org/10.1016/S2213-8587(26)00275-5
- **Original Source**: https://pubmed.ncbi.nlm.nih.gov/43033821/

## Summary

A weekly injection combining two drugs, cagrilintide and semaglutide, helped adults with overweight lose about a fifth of their body weight. It did so at doses below the 2.4 milligrams of each drug tested in earlier large trials. This study tried 1.7 and 1.0 milligrams of each.

The trial ran at 24 clinics in Canada, France, Germany, the UK and the US. It enrolled 309 adults without diabetes, on average 48 years old, about three quarters of them women. Chance decided who injected the drug and who injected a dummy shot for 68 weeks. Everyone also received advice on diet and activity. Weight fell by an average of 20.7 percent on the 1.7 mg dose, 21.0 percent on the 1.0 mg dose and 2.0 percent on the dummy shot. These figures assume everyone kept injecting as planned.

Nearly everyone reported side effects, including 91 percent of the dummy-shot group. Most were mild or moderate and affected the stomach and gut. No one died. The two doses were not tested head to head. The drug company Novo Nordisk paid for the study.

## Practical Takeaway

Adults with overweight lost about a fifth of their body weight on CagriSema, even at 1.7 or 1.0 milligrams of each drug.

---

_Canonical: https://longevity-cities.com/en/research/lower-dose-cagrisema-cuts-body-weight-by-about-a-fifth · Part of Longevity Cities · Updated 2026-11-20_
